We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1076
United Therapeutics
UTHR
$23.2B
| $1.22M | ﹤0.01% |
4,246
-470
| -10% | -$140K |
2013 Q2
48 quarters
|
|
1077
Fortive
FTV
$17.5B
| $1.21M | ﹤0.01% |
23,239
-28,389
| -55% | -$1.49M |
2016 Q3
35 quarters
|
|
1078
Protolabs
PRLB
$2.09B
| $1.21M | ﹤0.01% |
30,233
-5
| -0% | -$186 |
2021 Q4
14 quarters
|
|
1079
DELISTED
Semrush
SEMR
| $1.2M | ﹤0.01% |
133,024
-180,210
| -58% | -$1.74M |
2023 Q4
6 quarters
|
|
1080
BJs Wholesale Club
BJ
$13B
| $1.2M | ﹤0.01% |
11,107
-194
| -2% | -$22.1K |
2018 Q4
26 quarters
|
|
1081
American Public Education
APEI
$899M
| $1.2M | ﹤0.01% |
39,286
-78
| -0.2% | -$2.06K |
2013 Q2
48 quarters
|
|
1082
American Vanguard Corp
AVD
$36.9M
| $1.19M | ﹤0.01% |
303,179
+238,822
| +371% | +$996K |
2025 Q1
1 quarter
|
|
1083
Albemarle Corp Depositary Shares
ALB.PRA
$1.98B
| $1.19M | ﹤0.01% |
37,000
| – | – |
2024 Q1
5 quarters
|
|
1084
8x8 Inc
EGHT
$299M
| $1.19M | ﹤0.01% |
605,603
-19,174
| -3% | -$33.9K |
2022 Q1
13 quarters
|
|
1085
PTC Therapeutics
PTCT
$5.09B
| $1.19M | ﹤0.01% |
24,284
-51,061
| -68% | -$2.42M |
2024 Q4
2 quarters
|
|
1086
NeoGenomics
NEO
$2.22B
| $1.18M | ﹤0.01% |
161,683
+255
| +0.2% | +$2.06K |
2015 Q4
38 quarters
|
|
1087
Semtech
SMTC
$13.5B
| $1.18M | ﹤0.01% |
26,117
-163,628
| -86% | -$5.82M |
2024 Q2
4 quarters
|
|
1088
EVgo
EVGO
$157M
| $1.18M | ﹤0.01% |
322,678
+855
| +0.3% | +$2.93K |
2025 Q1
1 quarter
|
|
1089
DELISTED
HarborOne Bancorp
HONE
| $1.17M | ﹤0.01% |
99,901
+314
| +0.3% | +$3.43K |
2024 Q3
3 quarters
|
|
1090
Roper Technologies
ROP
$37.8B
| $1.16M | ﹤0.01% |
2,050
-2,550
| -55% | -$1.44M |
2013 Q2
48 quarters
|
|
1091
Neurocrine Biosciences
NBIX
$13.9B
| $1.16M | ﹤0.01% |
9,239
-202
| -2% | -$23.2K |
2017 Q2
32 quarters
|
|
1092
DELISTED
Simulations Plus
SLP
| $1.16M | ﹤0.01% |
66,459
+55,259
| +493% | +$1.55M |
2025 Q1
1 quarter
|
|
1093
Encompass Health
EHC
$12.6B
| $1.15M | ﹤0.01% |
9,410
-130
| -1% | -$14.8K |
2018 Q1
29 quarters
|
|
1094
ITT
ITT
$18B
| $1.15M | ﹤0.01% |
7,347
-361
| -5% | -$51.4K |
2013 Q2
48 quarters
|
|
1095
BancFirst
BANF
$3.63B
| $1.15M | ﹤0.01% |
9,312
+37
| +0.4% | +$4.4K |
2022 Q2
12 quarters
|
|
1096
D.R. Horton
DHI
$39B
| $1.15M | ﹤0.01% |
8,921
-6,696
| -43% | -$825K |
2015 Q1
41 quarters
|
|
1097
First Horizon
FHN
$10.8B
| $1.15M | ﹤0.01% |
54,125
+4,507
| +9% | +$85.9K |
2013 Q2
48 quarters
|
|
1098
Signet Jewelers
SIG
$4.53B
| $1.14M | ﹤0.01% |
14,340
-597
| -4% | -$39.7K |
2023 Q1
9 quarters
|
|
1099
Phinia Inc
PHIN
$2.12B
| $1.14M | ﹤0.01% |
25,601
-43,210
| -63% | -$1.82M |
2023 Q3
7 quarters
|
|
1100
Jones Lang LaSalle
JLL
$14.3B
| $1.14M | ﹤0.01% |
4,445
-6,777
| -60% | -$1.55M |
2013 Q2
48 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.